Overview

Gender

male

Dr. Ainscow has 15 years of working on innovative approaches to early drug discovery. His previous roles include Associate Director, Advanced Science and Technology Laboratory at AstraZeneca and Director at the Genomics Institute of the Novartis Research Foundation (GNF) where he headed the lead generation and compound profiling platforms and developed innovative technologies for early drug discovery.

Dr. Ainscow studied Natural Sciences at Cambridge University, specialising in Biochemistry. He then stayed on at Cambridge to obtain his Ph.D. in hepatic metabolism. He subsequently became an MRC Research Fellow at Bristol University studying insulin secretion in islet ?-cells. Dr. Ainscow then joined AstraZeneca where he pioneered the use of high throughput imaging for drug discovery screens. He then joined GNF to lead the HTS, compound profiling and combinatorial screening platforms. Dr. Ainscow has been at the forefront of the use of phenotypic approaches in early drug discovery and currently is a member of the planning committee of the Society for Lab Automation and Screening.